This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Invasive fungal infections in solid organ transplant recipients
Invasive fungal infections and chronic obstructive pulmonary disease
Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.
The oral and IV dosage of CRESEMBA® is fixed and simple, with a once-daily maintenance regimen and no need to adjust by weight.1
With high oral bioavailability (98%), the IV and oral formulations can be used interchangeably,1 which can help facilitate the switch from hospital to home care.
Simple and interchangeable IV and oral dosing¹
For long-term treatment beyond 6 months, the benefit-risk balance should be carefully considered.
Linear and predictable PK
CRESEMBA® has a linear PK profile up to 600 mg/day, with low inter-patient and intra-patient variability.1-4
TDM is not routinely recommended for CRESEMBA®.1,4,5 Management should be directed in accordance with local Trust policy.
CRESEMBA® can be taken with or without food.1,6
No dose adjustment is necessary with CRESEMBA® for:
a. CRESEMBA® has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); use in these patients is not recommended unless the potential benefit outweighs the risks. These patients should be carefully monitored for potential drug toxicity.1
CRESEMBA® interacts with selected CYP450 isoenzymes to a lesser degree than other azoles.1,3
Dose adjustments are not required for CRESEMBA® in combination with several commonly used medications.1
Unlike other azoles, CRESEMBA® can also be used with ibrutinib, and coadministration appears to be well tolerated.10,11
| Recommendations for the coadministration of CRESEMBA® with key medications1,b | ||
| Concomitant medication |
|
|
| Recommendation | No dose adjustment for either CRESEMBA® or the concomitant medication | Monitoring of concomitant medication and dose adjustment if required |
| Please refer to the CRESEMBA® Summary of Product Characteristics for full list of drug interactions and recommendations concerning coadministration. b. CRESEMBA® is contraindicated in coadministration with ketoconazole, high-dose ritonavir, and strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates, phenytoin and St. John’s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine.1 Coadministration with prednisolone, aprepitant, pioglitazone, should be avoided unless the potential benefit outweighs the risk. For further details and a full list of drug interactions, please consult the Summary of Product Characteristics. |
||
CRESEMBA® IV does not contain sucrose, can be diluted with saline or dextrose, and can be used with common anti-diabetes therapies such as metformin (metformin dose reduction may be required) and repaglinide.1
CRESEMBA® offers a simple dosing regimen with lower potential for drug interactions than other azoles,1,7–9 giving you the flexibility you need for complex clinical scenarios
Prescribing Information:
Click here for CRESEMBA® (isavuconazole) and Vfend (voriconazole) prescribing information
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021